HiberCell
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Pipeline
  • Patients & Caregivers
  • News & Publications
  • Contact
  • Careers
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Pipeline
  • Patients & Caregivers
  • News & Publications
  • Contact
  • Careers

Publication Topic: Preclinical

Cancer immunotherapy via myeloid signaling pathway co-activation (Wattenberg et al. AACR Pancreatic Cancer 2022)

A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Imprime (β-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma

Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth in vivo

Imprime PGG, a soluble yeast β-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

Binding of soluble yeast β-glucan to human neutrophils and monocytes is complement-dependent

HiberCell
  • About
    • Mission
    • Team
  • Our Science
    • Our Science
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Pipeline
  • News & Publications
  • Contact
  • Careers
Linked In

© 2023 Hibercell Inc |
Privacy Policy |
Terms & Conditions |
Expanded Access